StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $0.29 | $0.29 | -0.34% | 4.5M |
| 05-18 | $0.28 | $0.27 | -2.36% | 0.6M |
| 05-19 | $0.27 | $0.27 | -0.37% | 0.8M |
| 05-20 | $0.63 | $0.53 | -15.89% | 328.0M |
| 05-21 | $0.44 | $0.47 | +8.82% | 6.4M |
No sell-side coverage available for SLXN yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $32.00K | $155.00K | $86.00K | $46.00K |
Operating Income | $-2.75M | $-11.63M | $-7.23M | $-3.93M |
Net Income | $-2.73M | $-11.91M | $-7.50M | $-4.24M |
EPS (Diluted) | $0.85 | $8.96 | $10.36 | $8.21 |
Total Assets | $4.60M | $7.21M | $11.61M | $5.80M |
Total Liabilities | $4.31M | $4.61M | $4.64M | $5.68M |
Cash & Equivalents | $2.41M | $5.99M | $9.24M | $3.47M |
Free Cash Flow OCF − CapEx | $-3.65M | $-10.83M | $-7.81M | $-4.97M |
Shares Outstanding | 3.13M | 3.13M | 3.13M | 579.54K |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.